Anatumomab mafenatox explained

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]

Development was abandoned in 2005.[4]

Notes and References

  1. Web site: Active Biotech. activebiotech.com. 25 May 2016.
  2. Book: Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson M . Fusion Protein Technologies for Biopharmaceuticals. Tumor-Targeted Superantigens. 2013. 365–381. 10.1002/9781118354599.ch24. 9781118354599.
  3. Web site: Drug info. World Health Organization. 25 May 2016.
  4. Web site: Anatumomab mafenatox . AdisInsight . Springer Nature Switzerland AG.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Anatumomab mafenatox".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.